News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
Resistance
Computer models predict how patients will respond to HIV drugs

Results of a new study demonstrate that computer models can predict how HIV patients whose drug therapy is failing will respond to a new treatment. Crucially for patients in poorer countries, the models do not require the results of expensive drug resistance tests to make their predictions. The study also showed that the models were able to identify alternative drug combinations that were predicted to work in cases where the treatment used in the clinic had failed, suggesting that their use could avoid treatment failure.

Published
14 March 2013
From
Eurekalert Inf Dis
Treatment-experienced people
New integrase inhibitor dolutegravir helps treatment-experienced people on failing therapy

The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for treatment-experienced people with resistance to two or more antiretroviral drug classes, researchers reported in a poster

Published
10 March 2013
By
Liz Highleyman
Changing treatment
Second-line NRTI-sparing regimen proves equally effective for resource-limited settings

A second-line antiretroviral regimen of lopinavir/ritonavir (Kaletra/Aluvia) and raltegravir (Isentress) proved just as effective as a regimen containing lopinavir/ritonavir and two or three nucleoside or nucleotide analogues

Published
07 March 2013
By
Keith Alcorn
New and experimental HIV treatments
Can people with resistant HIV omit NRTIs when switching from a failing regimen?

Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least two active agents can reduce pill burden and

Published
07 March 2013
By
Liz Highleyman
Starting treatment
Meta-analysis shows superiority of integrase inhibitors in first-line HIV therapy and benefits for people changing treatment due to resistance

Antiretroviral combinations based on an integrase inhibitor are superior to other first-line HIV treatment regimens, according to the results of a meta-analysis published in the open access journal

Published
26 February 2013
By
Michael Carter
HIV treatment
It's tough to make predictions

“Generic HIV drugs 'less effective',” said the BBC headline. The article continued: “Any rise in the use of cheaper, non-branded HIV drugs could see more patients with treatment

Published
14 February 2013
From
HIV treatment update
Outcomes and prognosis
Australian researchers project that many HIV-positive people will run out of treatment options

Running out of antiretroviral treatment options may severely curtail the life expectancy of people with HIV in resource-rich countries, according to Australian research published in

Published
22 January 2013
By
Michael Carter
Changing treatment
PI monotherapy for HIV — an idea whose time has passed?

Patients who switched from suppressive triple-drug therapy to boosted protease-inhibitor monotherapy had unreasonably high rates of treatment failure.

Published
05 December 2012
From
Journal Watch
Treatment guidelines
Swiss research identifies factors associated with use of non-recommended HIV therapy

New Swiss research shows the importance of observing antiretroviral treatment guidelines, even in people who have well-controlled HIV infection. Published in the online edition of the Journal

Published
05 December 2012
By
Michael Carter
Changing treatment
Raltegravir-resistant HIV stays susceptible to dolutegravir in lab

HIV resistant to the integrase inhibitor raltegravir and isolated from patients taking a failing raltegravir regimen remained largely susceptible to the integrase inhibitor dolutegravir in phenotypic susceptibility testing. Raltegravir-resistant virus carrying a mutation at position Q148 had more reduced susceptibility to dolutegravir than isolates with other raltegravir mutations.

Published
13 November 2012
From
International AIDS Society
← First12345...21Next →

Filter by country